Literature DB >> 19172926

Audit of prescription of anti-malarial prophylaxis to patients admitted to Royal Centre for Defence Medicine (RCDM) following evacuation from Afghanistan.

J Penn-Barwell1, S Pengelly.   

Abstract

INTRODUCTION: For most of the year Military personnel deployed to Afghanistan are required to take anti-malarial chemoprophylaxis (AMC). This audit aims to quantify how many personnel taking AMC in theatre have it continued at RCDM.
METHOD: A database kept at RCDM was searched for details of all evacuated patients. Records of these patients were then searched to find out which had been admitted, how many had been taking AMC prior to admission and how many were prescribed it in hospital.
RESULTS: During the study period 40 patients were evacuated to RCDM. 26 of these were admitted and had notes available and were therefore included in the study. 9 of these had been taking AMC prior to admission; of them, only 4 had been continued on AMC by the time they were admitted to RCDM.
CONCLUSION: Insufficient numbers of patients taking AMC prior to admission have it continued as an inpatient. Awareness of this issue needs to be raised at all points of the medical evacuation chain.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19172926

Source DB:  PubMed          Journal:  J R Nav Med Serv        ISSN: 0035-9033


  2 in total

1.  Compliance with antimalarial chemoprophylaxis recommendations for wounded United States military personnel admitted to a military treatment facility.

Authors:  Elizabeth A Rini; Amy C Weintrob; David R Tribble; Bradley A Lloyd; Tyler E Warkentien; Faraz Shaikh; Ping Li; Deepak Aggarwal; M Leigh Carson; Clinton K Murray
Journal:  Am J Trop Med Hyg       Date:  2014-04-14       Impact factor: 2.345

2.  Bibliographic review of research publications on access to and use of medicines in low-income and middle-income countries in the Eastern Mediterranean Region: identifying the research gaps.

Authors:  Arash Rashidian; Nader Jahanmehr; Samer Jabbour; Shehla Zaidi; Fatemeh Soleymani; Maryam Bigdeli
Journal:  BMJ Open       Date:  2013-10-03       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.